Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Account Payables

Amounts the company owes suppliers for goods and services received.

Xencor, Inc.NASDAQ: XNCR

Account Payables · Q2 FY2026 · quarter ended Jun 2026

Account payables falls 31.8% from a year ago

Account payables stood at $12.65M at the end of Q2 FY2026, down 31.8% from a year earlier and up 59.7% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Account payables amounted to 1.7% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -31.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.65M+59.7% QoQ
Last fiscal yearDec 2025
$10.83M-35.4% YoY
Year agoJun 2025
$18.53M-31.8% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.8%——
1 year-35.4%——
3-year CAGR+2.4%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
10.83M USD
Year-over-year change
-35.4%
4-year CAGR
-6.2%

Account Payables vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -31.8% is the 7th highest of 10, against a peer median of +74.3%.
  • Account payables amounts to 1.7% of total assets for XNCR, versus a peer median of 2.5%.
XNCR Competitors
Account Payables for XNCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$32.98M USD+283.1%+30.3%2.8%
IMCRImmunocore Holdings plcMar 2026$30.16M USD+3.6%+19.0%2.8%
NKTRNektar TherapeuticsJun 2026$24.89M USD+74.3%-6.0%2.3%
IPHAInnate Pharma S.A.Dec 2025€15.04M EUR+89.8%+3.3%24.0%
XNCRXencor, Inc.Jun 2026$12.65M USD-31.8%+2.4%1.7%
CLDXCelldex Therapeutics, Inc.Sep 2026$11.24M USD+163.4%-29.3%1.6%
IMMPImmutep LimitedDec 2025A$9.03M AUD+126.7%+24.5%6.1%
MGNXMacroGenics, Inc.Mar 2026$4.29M USD-35.2%-0.8%2.0%
ADAGAdagene Inc.Dec 2025$2.88M USD-32.0%-7.7%3.7%
CGENCompugen Ltd.Mar 2026$2.53M USD-76.9%+9.9%1.7%
GMABGenmab A/SJun 2026$0 USD——0.0%
Peer median (excluding XNCR) —+74.3%+3.3%2.5%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents143.48M53.94M53.79M40.88M54.07M
Short-term Investments190.63M569.12M539.94M456.9M493.66M
Net Receivables66.38M29M11.29M60.85M29.3M
Inventory00000
Other Current Assets023.28M18.15M18.98M22.79M
Total Current Assets424.37M675.34M623.16M577.6M599.82M
Property, Plant & Equipment (Net)59.97M93.6M100.12M98.14M90.9M
Goodwill00000
Intangible Assets16.49M18.5M18.66M18.49M8.39M
Long-term Investments331.73M58.21M209.72M256.83M175.89M
Tax Assets5M0000
Other Non-current Assets653K613K1.03M885K498K
Total Non-current Assets413.84M170.92M329.53M374.34M275.67M
Total Assets838.21M846.27M952.69M951.95M875.5M
Account Payables14M10.09M13.91M16.76M10.83M
Short-term Debt006.33M48.45M43.27M
Tax Payables005.78M9.99M3.59M
Deferred Revenue37.29M30.32M31.68M00
Other Current Liabilities00000
Total Current Liabilities70.74M63.84M84.71M87.43M95.91M
Long-term Debt0014.64M115.16M76.48M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00125.18M00
Other Non-current Liabilities0009.99M2.78M
Total Non-current Liabilities33.97M54.93M198.85M190.49M144M
Total Liabilities104.71M118.77M283.56M277.92M239.91M
Common Stock595K601K611K703K718K
Retained Earnings(283.1M)(338.29M)(464.37M)(704.04M)(795.96M)
Accumulated OCI(1.51M)(6.95M)1.29M(663K)1.58M
Other Stockholders Equity00000
Minority Interest00337K(3.59M)0
Total Equity733.5M727.5M669.13M674.03M635.59M
Total Debt33.97M59.63M83.43M231.95M187.75M
Net Debt(109.51M)5.69M29.64M191.08M133.67M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.